arrow
A

A. Tryakin

n n blokhin national medical research center of oncology
H指数:17
被引数:1,940

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Profiling of CD63 and EpCAM Membrane Proteins of Extracellular Vesicles on Tannic Acid-Coated Magnetic Beads Using Conventional Flow Cytometry

使用常规流式细胞术对茶多酚包被磁珠上外泌体CD63和EpCAM膜蛋白进行表征

2026-03-030
OAAI
The Role of MSI Testing Methodology and Its Heterogeneity in Predicting Colorectal Cancer Immunotherapy Response

微卫星不稳定性检测方法及其异质性在预测结直肠癌免疫治疗反应中的作用

2025-04-050
OA
Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2-, High-risk Early Breast cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-year Efficacy Outcomes

HR+, HER2-,高风险早期乳腺癌的辅助Abemaciclib联合内分泌疗法:来自预先计划的monarchE研究总生存期中期分析的结果,包括5年疗效结局

BREAST
IF7.9
2025-02-010
OAAI
Molecular-genetic concordance of the primary tumor and brain metastases of colorectal cancer (GENCONCOR-1): second interim analysis

结直肠癌原发灶与脑转移灶的分子-遗传学一致性(GENCONCOR-1):第二次中期分析

2024-12-010
PRE
A multicenter randomized clinical trial evaluating the negative hyperselection of patients with RAS/BRAF wild-type metastatic colorectal cancer who are eligible for anti-EGFR therapy

一项多中心随机临床试验,评估接受抗-EGFR治疗的RAS/BRAF野生型转移性结直肠癌患者的阴性超选择。

2024-09-010
PRE
Characteristics and palliative management of patients with cisplatin-refractory germ cell tumours: A Global Germ Cell Cancer Collaborative Group (G3) retrospective registry study

顺铂耐药性生殖细胞肿瘤患者的特点与姑息管理:全球生殖细胞癌协作组(G3)回顾性登记研究

2024-09-010
PRE
Paclitaxel, ifosfamide and cisplatin (TIP) in patients (pts) with poor prognosis nonseminomatous germ cell tumor (NSGCT) with unfavourable serum tumor markers (STM) decline: A phase II study

紫杉醇、异环磷酰胺和顺铂(TIP)在不良预后非精原细胞性生殖细胞肿瘤(NSGCT)且血清肿瘤标志物(STM)下降不佳的患者(pts)中的应用:一项II期研究

2024-09-010
PRE
Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium

畸胎瘤对转移性非精原细胞性生殖细胞癌患者生存概率的影响: IGCCCG更新联盟的结果

2024-05-010
PRE
Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
2023-11-010
PRE
Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes
2023-10-0110
OA